Harvard Bioscience (HBIO) Invested Capital (2013 - 2025)

Harvard Bioscience (HBIO) has 13 years of Invested Capital data on file, last reported at $34.0 million in Q3 2025.

• On a quarterly basis, Invested Capital rose 841.96% year-over-year to $34.0 million in Q3 2025; TTM through Mar 2026 was $68.8 million, a 14.22% decrease from a year earlier, with the FY2024 full-year figure at $37.0 million, up 530.76% from the prior year.
• Invested Capital for Q3 2025 stood at $34.0 million, down from $34.9 million in the prior quarter.
• Over the last five years, Invested Capital for HBIO reached as high as $37.0 million in Q4 2024 and fell as low as $2.0 million in Q1 2021.
• Historically, Invested Capital has averaged $10.0 million across 5 years, with a median of $3.5 million in 2023.
• Across the five-year window, Invested Capital declined 29.82% in 2021 and surged 866.61% in 2025, its largest moves.
• Year by year, Invested Capital stood at $3.2 million in 2021, then increased by 17.81% to $3.8 million in 2022, then surged by 53.74% to $5.9 million in 2023, then surged by 530.76% to $37.0 million in 2024, then dropped by 8.09% to $34.0 million in 2025.
• Per Business Quant data, the three most recent Invested Capital figures were $34.0 million in Q3 2025, $34.9 million in Q2 2025, and $36.0 million in Q1 2025.